Migraine market set to grow to $8.7 billion by 2026; report

Sales of migraine products are expected to grow to $8.7 billion by 2026, at a compound annual growth rate (CAGR) of 10.3% across the seven major markets (5EU (France, Germany, Italy, Spain, and the UK), and Japan; 7MM).

According to business information and analytics firm GlobalData, the USA will continue to dominate the market with a 77% share of total sales by 2026 followed by Germany (5.6%) and Italy (5.2%).

The company’s latest report: ‘PharmaPoint: Migraine Global Drug Forecast and Market Analysis to 2026' confirms that market growth will be driven by the launch of several late-stage pipeline products, particularly the calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) erenumab, galcanezumab, fremanezumab, and eptinezumab, developed by Amgen (Nasdaq: AMGN), Eli Lilly (NYSE: LLY), Teva Pharmaceutical Industries (NYSE: TEVA), and Alder BioPharmaceuticals (Nasdaq: ALDR) respectively.

The current migraine treatment landscape is mainly dominated by generic drugs, as the majority of migraine drugs have seen their patents expire. However current treatments leave a large number of patients undertreated; many of the drugs, for both acute and preventative treatment, have poor efficacy profiles which are ineffective in a large number of patients. In addition to this, many of these drugs are contraindicated in patients with certain co-morbidities.

Rahael Maladwala, healthcare analyst at GlobalData, commented: ‘‘Comorbidities exacerbate the economic and social burden of migraine due to increased utilization of healthcare resources and lower quality of life. Understanding the association between migraine and comorbid conditions is essential for better management of migraine.’’